# Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

> **NCT03188198** · PHASE2 · UNKNOWN · sponsor: **Mansoura University** · enrollment: 60 (estimated)

## Conditions studied

- Large B Cell Lymphoma

## Interventions

- **DRUG:** rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim

## Key facts

- **NCT ID:** NCT03188198
- **Lead sponsor:** Mansoura University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-01
- **Primary completion:** 2018-06-01
- **Final completion:** 2019-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188198, "Risk Adapted Therapy in Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03188198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*